100%
Skip to main content
Platform
GovTribe AI
AI-powered insights to accelerate your government contracting workflow.
MCP Server
Connect GovTribe to your AI tools.
Beacon
Find and connect with key government decision-makers.
Profiles
Federal Agencies
Federal Contract Vehicles
Federal Grant Programs
Major Defense Acquisition Programs
NAICS Categories
PSC Categories
States
Jurisdictions
NIGP Categories
UNSPSC Categories
Vendors
Enrichment By Clearbit
Reports
New Entrants
Funding Analysis
Vehicle Analysis
Groups
Capture
Pipelines
Pursuits
Alerts
Teaming
Data
Awards
Forecasts
Federal Opportunities
State & Local Opportunities
Files
Prime and Subcontractors
Activity
Search
Exports
Solutions
Use Case
Opportunity Identification
Capture Management
Competitive Intelligence
Teaming & Partner Identification
Proposal Management
Strategic Leadership
Go-to-Market Strategy
Industry
Federal Contractors
State & Local Contractors
Grant Seekers
Government Agencies
Research & Consulting
Pricing
More
About Us
Features
Get A Demo
Sign Up
Blog
User Guide
Data Model
GovTribe for Agents
Login
Contact sales
Try for free
Login
Contact sales
Try for free
All Federal Contract Awards
Purchase Order 75N90021P00581
Award Date
7/19/21
Potential Completion Date
8/18/21
Potential Value
$51K
Overview
Contacts
Activity
1
Transactions
1
Subawards
Opportunity Stack
Similar Awards
Federal Agency
NIH Clinical Center
Awardee
Cellgenix USA CCYHJN1KNAM6
Ultimate Awardee
Not listed
NAICS Category
325414 - Biological Product (except Diagnostic) Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Portsmouth, NH 03801, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Description
VARIOUS CELLGENIX CYTOKINES REAGENTS.
Posted 7/19/21
5
1
Name
Description
Solicitation Number
FederalAgency
Type
PostedDate
CellGenix USA/ Various CellGenix cytokines for X-SCID.
INTRODUCTION This is not a request for a quotation. A solicitation document will not be issued and quotations will not be requested. THIS IS A PRE-SOLICITATION NON-COMPETITIVE (NOTICE OF INTENT) SYNOPSIS TO AWARD A CONTRACT OR PURCHASE ORDER WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME). The National Institutes of Health (NIH), Clinical Center (CC), Office of Purchasing and Contracts (OPC) on behalf of the Center for Cellular Engineering (CCE), Clinical Center (CC) at the National Institutes of Health (NIH) intends to negotiate and award a contract without providing for full and open competition (including brand-name) to: CELLGENIX USA 1 Nh AVE Portsmouth, NH 03801-2904 United States NORTH AMERICAN INDUSTRY CLASSIFICATION SYSTEM (NAICS) CODE The intended procurement is classified under NAICS code 325413 with a Size Standard 1250. REGULATORY AUTHORITY The resultant contract will include all applicable provisions and clauses in effect tough the Federal Acquisition Circular (FAC) 2021-05 March 10, 2021. This acquisition is conducted under the procedures as prescribed in FAR subpart 13-Simplified Acquisition Procedures at an amount not exceeding the simplified acquisition teshold. STATUTORY AUTHORITY This acquisition is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13-Simplified Acquisition Procedures, Subpart 13.106-1 (b) (1), Soliciting from a single source and is not expected to exceed the simplified acquisition teshold. Contracts awarded using FAR Part 13-Simplified Acquisition Procedures are exempt from the requirements of FAR Part 6-Competition Requirements. GENERAL INFORMATION 1. Title: CellGenix USA/ Various CellGenix cytokines for X-SCID. 2. Background Information: The Center Cellular Engineering (CCE) is an AABB accredited cellular therapy laboratory whose central mission is to provide services to the NIH Institutes to support more than 50 intramural clinical trials. These services include (1) development, evaluation, and validation of investigational new drugs (INDs) for cellular therapies and (2) manufacture of cellular therapy products for approved clinical trials. The majority of these trials are early phase (I/II) trials not intended to result in the development of a commercial product. To provide these services, CCE operates a core facility for the manufacture, storage, and distribution of cellular therapy products. CCE manufactures cellular therapy products from more than 800 collections from patients or healthy donors per year. The products manufactured by the laboratory are used to treat NIH CC patients with cancer, hematological malignancies, marrow failure, genetic immune disorders and autoimmune diseases. All products are manufactured using good manufacturing practices (GMP). The NIH protocols are institutional review board (IRB) approved and in the case of INDs, approval by the US Food and Drug Administration (FDA) for treatment of human subjects. Each subject must consent to participate in a NIH Clinical Research Study. 3. Purpose or Objective: To procure the selected CellGenix Cytokines in the preparation for treatment of patient with X-Linked Severe Deficient Severe Combined Immunodeficiency (X-SCID) enrolled in FDA approved clinical protocols. IND is only allowing cytokines from this manufacturer to be used, prohibit the substitution of any reagent/process named in the original protocol submissions. 4. The Vendor will supply reagents as needed in a timely manner no later than 8/4/21. The reagents include but not are not limited to those listed below: Description Quantity GMP FLT-3L, 50 ug (Cat.# 001015-050) 9 GMP SCF, 50 ug (Cat.# 001018-050) 9 GMP TPO, 50 ug (Cat.# 001017-050) 9 CellGenix GMP rh IL-7 (Cat. # 001010-050) 6 CellGenix GMP rh IL-21 (Cat. # 001019-050) 4 CellGenix GMP rh IL-15 (Cat. #001013-050) 4 The Vendor shall supply technical support for all reagents and their performance characteristics at no additional cost to the Government. Delivery Schedule: 8/4/21 SHIP TO: Katy Burkert CCE/CC/NIH Bldg 10, Room 3C720 9000 Rockville Pike Bethesda, MD 20892 -The contractor shall bear the cost of replacement for reagents found to be damaged or defective upon receipt by NIH or for incorrect or incomplete shipments. Government Responsibilities The CCE shall inspect shipments upon receipt and report any damage, defects or errors in shipment to the contractor. CONTRACTING WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME) DETERMINATION This system is on site and has been validated for use on CC patients. It would be detrimental to the government to attempt to change systems and quite impossible as these instruments are proprietary and only distributed by CellGenix USA. With the continuation of using the same system will also help reduces the risk of a disruption in patient care. The determination by the Government to award a contract without providing for full and open competition is based upon the market research conducted as prescribed in FAR Part 10-Market Research. CLOSING STATEMENT This synopsis is not a request for competitive proposals. However, interested parties may identify their interest and capability to respond to this notice. Responses to this notice shall contain sufficient information to establish the interested parties' bona-fide capabilities for fulfilling the requirement and include a technical proposal, a cost-price proposal, and the period of performance, the Dun & Bradstreet Number (DUNS), the Taxpayer Identification Number (TIN), and the certification of business size. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. The information received will normally be considered solely for the purposes of determining whether to proceed on a non-competitive basis or to conduct a competitive procurement. All responses must be received by July 15th, 2021, 11:00 AM Eastern time and must reference solicitation number 21-010644. Responses may be submitted electronically to Mrs. Grace Wong-Darko, Contracting Specialist at Grace.Wong-Darko@nih.gov. Fax responses will not be accepted. "All responsible sources may submit a capability statement, proposal, or quotation, which shall be considered by the agency."
21-010644
Department of Health and Human Services National Institutes of Health Clinical Center
Pre-Solicitation 1/1
7/8/21, 10:50 AM
5
1
Mod #
Description
ReasonForModification
Federal Obligation
Date
Not listed
VARIOUS CELLGENIX CYTOKINES REAGENTS.
Not listed
$51.4k
7/19/21